Clinical and Translational Oncology

, Volume 10, Issue 9, pp 552–559 | Cite as

Diagnosis and medical treatment of breast cancer. Cordoba Consensus of 2007

  • Juan De la Haba-RodriguezEmail author
  • Emilio Alba
  • Agustí Barnadas
  • Eloisa Bayo
  • Antonio Llombart
  • Ana Lluch
  • Miguel Martín
  • José Andrés Moreno-Nogueira
  • Gumersindo Pérez Manga
  • Álvaro Rodríguez-Lescure
  • Enrique Aranda
Special Article


Many important studies have changed the perspective from which breast cancer is approached, and they may change what have to date been the standards applicable to the diagnosis and treatment of breast cancer. In 2007, just over 200 oncologists from all over Spain met in Cordoba in order to review the latest evidence related to breast cancer and reach a consensus on the most important aspects of its diagnosis and treatment in different clinical situations: neoadjuvance, adjuvance and advanced disease. In view of these important changes, opinions on some specific aspects may be varied and all are justified. This document represents a review of the current state of the evidence.


Breast cancer Diagnosis Prognostic factors Treatment 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cobleigh MA, Tabesh B, Bitterman P et al (2005) Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 11:8623–8631PubMedCrossRefGoogle Scholar
  2. 2.
    (2006) NSABP study confirms oncotype DX predicts chemotherapy benefit in breast cancer patients. Oncology (Williston Park) 20:789–790Google Scholar
  3. 3.
    Mook S, Van’t Veer LJ, Rutgers EJ et al (2007) Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics 4:147–155PubMedGoogle Scholar
  4. 4.
    Perou CM, Jeffrey SS, van de Rijn M et al (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci USA 96:9212–9217PubMedCrossRefGoogle Scholar
  5. 5.
    Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRefGoogle Scholar
  6. 6.
    Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRefGoogle Scholar
  7. 7.
    Sotiriou C, Desmedt C (2006) Gene expression profiling in breast cancer. Ann Oncol 17[Suppl 10]:x259–x262PubMedCrossRefGoogle Scholar
  8. 8.
    Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRefGoogle Scholar
  9. 9.
    Olopade OI, Fackenthal JD, Dunston G et al (2003) Breast cancer genetics in African Americans. Cancer 97[1 Suppl]:236–245PubMedCrossRefGoogle Scholar
  10. 10.
    Kandel MJ, Stadler Z, Masciari S, et al (2006) Garber. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. Vol 24,18S[20 Supplement]:508Google Scholar
  11. 11.
    Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658–1667PubMedCrossRefGoogle Scholar
  12. 12.
    Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRefGoogle Scholar
  13. 13.
    (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 352:930–942Google Scholar
  14. 14.
    Martin M, Villar A, Sole-Calvo A et al (2003) Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group. Ann Oncol 14:833–842PubMedCrossRefGoogle Scholar
  15. 15.
    Wood WC, Budman DR, Korzun AH et al (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253–1259PubMedCrossRefGoogle Scholar
  16. 16.
    Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439PubMedCrossRefGoogle Scholar
  17. 17.
    Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976–983PubMedCrossRefGoogle Scholar
  18. 18.
    Mamounas E, Bryant J, Lembersky BC et al (2003) Paclitaxel (T) following doxorubicin/cyclophosphamide (AC) as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. Proc Am Soc Clin Oncol 22 [Abstr 12]Google Scholar
  19. 19.
    Martin M, Pienkowski T, Mackey J et al (2005) Breast Cancer International Research Group 001 Investigators. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302–2313PubMedCrossRefGoogle Scholar
  20. 20.
    Roché H, Fumoleau P, Spielmann M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 24:5664–5671PubMedCrossRefGoogle Scholar
  21. 21.
    Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387PubMedCrossRefGoogle Scholar
  22. 22.
    Martin M, Mackey J, Vogel C (2007) Benefit from adjuvant taxanes and endocrine responsiveness in breast cancer. Breast 16[Suppl 2]:S127–131. ReviewPubMedCrossRefGoogle Scholar
  23. 23.
    Goldhirsch A, Wood WC, Gelber RD et al (2003) Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357–3365PubMedCrossRefGoogle Scholar
  24. 24.
    (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 352:930–942Google Scholar
  25. 25.
    Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673–1684PubMedCrossRefGoogle Scholar
  26. 26.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672PubMedCrossRefGoogle Scholar
  27. 27.
    (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351:1451–1467Google Scholar
  28. 28.
    (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev (1):CD000486Google Scholar
  29. 29.
    Baum M (2002) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 38:1984–1986PubMedCrossRefGoogle Scholar
  30. 30.
    Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092PubMedCrossRefGoogle Scholar
  31. 31.
    Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793–1802PubMedCrossRefGoogle Scholar
  32. 32.
    Castiglione-Gertsch M, O’Neill A, Price KN et al (2003) Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J Natl Cancer Inst 95:1833–1846PubMedGoogle Scholar
  33. 33.
    Jonat W, Kaufmann M, Sauerbrei W et al (2002) Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 20:4628–4635PubMedCrossRefGoogle Scholar
  34. 34.
    Davidson NE (1994) Ovarian ablation as treatment for young women with breast cancer. J Natl Cancer Inst Monogr (16):95–99Google Scholar
  35. 35.
    Boccardo F, Rubagotti A, Amoroso D et al (1998) Italian Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group Trials. GROCTA Trials. Recent Results Cancer Res 152:453–470PubMedGoogle Scholar
  36. 36.
    Kaufmann M, von Minckwitz G, Smith R et al (2003) International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol 21:2600–2608PubMedCrossRefGoogle Scholar
  37. 37.
    Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194PubMedCrossRefGoogle Scholar
  38. 38.
    Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15:2483–2493PubMedGoogle Scholar
  39. 39.
    Sachelarie I, Grossbard ML, Chadha M et al (2006) Primary systemic therapy of breast cancer. Oncologist 11:574–589PubMedCrossRefGoogle Scholar
  40. 40.
    Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676–3685PubMedCrossRefGoogle Scholar
  41. 41.
    Dawood S, Gonzalez-Angulo AM, Peintinger F et al (2007) Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M.D. Anderson experience. Cancer 110:1195–1200PubMedCrossRefGoogle Scholar
  42. 42.
    Mustacchi G, Ceccherini R, Milani S (2003) Italian Cooperative Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multiceter GRETA trial. Ann Oncol 14:414–420PubMedCrossRefGoogle Scholar
  43. 43.
    Eiermann W, Paepke S, Appfelstaedt J et al (2001) Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532PubMedCrossRefGoogle Scholar
  44. 44.
    Ellis MJ, Rosen E, Dressman H, Marks J (2003) Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 86:301–307. ReviewPubMedCrossRefGoogle Scholar
  45. 45.
    Semiglazov VF, Semiglazov VV, Dashyan GA et al (2007) Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110:244–254PubMedCrossRefGoogle Scholar
  46. 46.
    Ivshina AV, George J, Senko O et al (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66:10292–10301PubMedCrossRefGoogle Scholar
  47. 47.
    Martín M (2006) Molecular biology of breast cancer. Clin Transl Oncol 8:7–14. ReviewPubMedCrossRefGoogle Scholar
  48. 48.
    Polychronis A, Sinnett HD, Hadjiminas D et al (2005) Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 6:383–391PubMedCrossRefGoogle Scholar
  49. 49.
    Klijn JG, Blamey RW, Boccardo F et al (2001) Combined Hormone Agents Trialists’ Group and the European Organization for Research and Treatment of Cancer. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 19:343–353PubMedGoogle Scholar
  50. 50.
    Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758–3767PubMedGoogle Scholar
  51. 51.
    Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258PubMedCrossRefGoogle Scholar
  52. 52.
    Mouridsen H, Gershanovich M, Sun Y et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101–2109PubMedCrossRefGoogle Scholar
  53. 53.
    Dixon AR, Jackson L, Chan SY et al (1993) Continuous chemotherapy in responsive metastatic breast cancer: a role for tumour markers? Br J Cancer 68:181–185PubMedGoogle Scholar
  54. 54.
    Falkson G, Gelman RS, Pandya KJ et al (1998) Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 16:1669–1676PubMedGoogle Scholar
  55. 55.
    Alba E, Martín M, Ramos M et al (2004) Spanish Breast Cancer Research Group. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587–2593PubMedCrossRefGoogle Scholar
  56. 56.
    Alba E, Ribelles N, Antón A et al (2003) GEICAM. Sequential doxorubicin and docetaxel as first-line treatment in metastatic breast cancer: a GEICAM-9801 phase II study. Breast Cancer Res Treat 77:1–8PubMedCrossRefGoogle Scholar
  57. 57.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  58. 58.
    Burris HA (2001) Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 28[1 Suppl 3]:38–44PubMedCrossRefGoogle Scholar
  59. 59.
    Montemurro F, Choa G, Faggiuolo R et al (2004) A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66:38–45PubMedCrossRefGoogle Scholar
  60. 60.
    Fisher B, Bauer M, Margolese R et al (1985) Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer. N Engl J Med 312:665–673PubMedGoogle Scholar
  61. 61.
    Fisher B, Anderson S, Redmond CK et al (1995) Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 333:1456–1461PubMedCrossRefGoogle Scholar
  62. 62.
    Liljegren G, Holmberg L, Bergh J et al (1999) 10-year results after sector resection with or without postoperative radiotherapy for stage 1 breast cancer: a randomized trial. J Clin Oncol 17:2326–2333PubMedGoogle Scholar
  63. 63.
    Clark RM, McCulloch PB, Levine MN et al (1992) Randomized clinical trial to assess the effectiveness of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer. J Natl Cancer Inst 84:683–689PubMedCrossRefGoogle Scholar
  64. 64.
    Veronesi U, Marubini E, Mariani L et al (2001) Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol 12:997–1003PubMedCrossRefGoogle Scholar
  65. 65.
    Forrest AP, Stewart HJ, Everington D et al (1996) Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Lancet 348:708–713PubMedCrossRefGoogle Scholar
  66. 66.
    Holli K, Saaristo R, Isola J et al (2001) Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study. Br J Cancer 84:164–169PubMedCrossRefGoogle Scholar
  67. 67.
    Early Breast Cancer Trialists’ Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 355:1757–1770CrossRefGoogle Scholar
  68. 68.
    Early Breast Cancer Trialists Collaborative Group (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on lo cal recurrence and 15-year survival: an over view of the randomised trials. Lancet 366:2087–2106Google Scholar
  69. 69.
    Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18:2817–2827PubMedGoogle Scholar
  70. 70.
    Truong PT, Lesperance M, Culhaci A et al (2005) Patient subsets with T1-T2, node-negative breast cancer at high locoregional recurrence risk after mastectomy. Int Radiat Oncol Biol Phys 62:175–182CrossRefGoogle Scholar
  71. 71.
    Ragaz J, Olivotto IA, Spinelli JJ et al (2005) Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia Randomized Trial. J Natl Cancer Inst 97:117–126Google Scholar
  72. 72.
    Overgaard M, Hansen PS, Overgaard J et al (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949–955PubMedCrossRefGoogle Scholar
  73. 73.
    Overgaard M, Jensen MB, Overgaard J et al (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 353:1641–1648PubMedCrossRefGoogle Scholar
  74. 74.
    Carlson RH (2007) Lumpectomy plus tamoxifen without radiation may be option for older patients with early breast cancer [San Antonio Breast Cancer Symposium]. Oncol Times 29:68,70Google Scholar
  75. 75.
    Fyles AW, McCready DR, Manchul LA et al (2004) Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 351:963–970PubMedCrossRefGoogle Scholar
  76. 76.
    Blamey RW, Chetty U, Mitchell A et al (2002) The BASO II trial of adjuvant radiotherapy vs none and tamoxifen vs none in small, node negative, grade I tumours. Eur J Cancer 38:S149 [Suppl 3; Abstr 413]CrossRefGoogle Scholar
  77. 77.
    Winzer KJ, Sauer R, Sauerbrei W et al (2004) Radiation therapy after breast-conserving surgery: first results of a randomized clinical trial in patients with low risk of recurrence. Eur J Cancer 40:998–1005PubMedCrossRefGoogle Scholar
  78. 78.
    Bartelink H, Horiot JC, Poortmans P et al (2001) Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 345:1378–1387PubMedCrossRefGoogle Scholar
  79. 79.
    Romestaing P, Lehingue Y, Carrie C et al (1997) Role of 10 Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 15:963–968PubMedGoogle Scholar
  80. 80.
    Teissier E, Héry M, Ramaioli A et al (1998) Boost in conservative treatment: 6 years results of randomized trial. Breast Cancer Res Treat 50:287 [Abstr 345]Google Scholar
  81. 81.
    Polgar C, Fodor J, Orosz Z et al (2002) Electron and high-dose-rate brachytherapy boost in the conservative treatment of stage I–II breast cancer. First results of the randomized Budapest boost trial. Strahlenther Onkol 178:615–623PubMedCrossRefGoogle Scholar

Copyright information

© Feseo 2008

Authors and Affiliations

  • Juan De la Haba-Rodriguez
    • 1
    Email author
  • Emilio Alba
    • 2
  • Agustí Barnadas
    • 3
  • Eloisa Bayo
    • 4
  • Antonio Llombart
    • 5
  • Ana Lluch
    • 6
  • Miguel Martín
    • 7
  • José Andrés Moreno-Nogueira
    • 8
  • Gumersindo Pérez Manga
    • 9
  • Álvaro Rodríguez-Lescure
    • 10
  • Enrique Aranda
    • 1
  1. 1.Medical Oncology DepartmentHospital Universitario Reina SofíaCórdobaSpain
  2. 2.Medical Oncology DepartmentHospital Universitario Virgen de la VictoriaMálagaSpain
  3. 3.Medical Oncology DepartmentHospital General de la Santa Creu i Sant PauBarcelonaSpain
  4. 4.Radiotherapy Oncology DepartmentHospital Juan Ramón JiménezHuelvaSpain
  5. 5.Medical Oncology DepartmentHospital Arnau de VilanovaLleidaSpain
  6. 6.Medical Oncology DepartmentHospital ClínicoValenciaSpain
  7. 7.Medical Oncology DepartmentHospital Clínico San CarlosMadridSpain
  8. 8.Medical Oncology DepartmentHospital Universitario Virgen del RocíoSevillaSpain
  9. 9.Medical Oncology DepartmentHospital Gregorio MarañónMadridSpain
  10. 10.Medical Oncology DepartmentHospital GeneralElche, AlicanteSpain

Personalised recommendations